Additionally, progression free survival (PFS) was significantly reduced in patients with MM taking concurrent PPAR agonists (median: 21.3 months) than in similar patients taking no PPAR agonists (median: 37.9 months) (p = 0.0374) (Figure 5, left panel). The gene discussed is PPARA; the disease is Miyoshi myopathy.